Alnylam Pharmaceuticals Inc

This innovative biotech stock has helped transform RNAi into an innovative new class of medicine. You have probably heard about RNA and mRNA innovation as the basis for the COVID-19 vaccine. This novel technology is set to shake up the medical world, and Alnylam is well-positioned to benefit from it.

$242.41
(as of Dec 26, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Alnylam Pharmaceuticals Inc

Stock Price
$242.41
Ticker Symbol
ALNY
Exchange
NASDAQ

Industry Information for Alnylam Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Alnylam Pharmaceuticals Inc

Website
https://www.alnylam.com
Country
USA
Full Time Employees
2,100

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Fundamentals for Alnylam Pharmaceuticals Inc

Market Capitalization
$31,374,628,864
EBITDA
$-132,146,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
909.09
Earnings per Share
$-2.63
Earnings per Share Estimate Next Year
$0.52
Profit Margin
-15.86%
Shares Outstanding
128,981,000
Percent Owned by Insiders
0.43%
Percent Owned by Institutions
98.01%
52-Week High
$304.39
52-Week Low
$141.98

Technical Indicators for Alnylam Pharmaceuticals Inc

50-Day Moving Average
$262.79
200-Day Moving Average
$222.13
RSI
41.4
ATR
7.8

Analyst Ratings for Alnylam Pharmaceuticals Inc

Strong Buy
11
Buy
11
Hold
8
Sell
1
Strong Sell
1

News About Alnylam Pharmaceuticals Inc

Oct 21, 2024, 11:52 AM EST
Novo Nordisk NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years or older living with haemophilia A or B with inhibitors. See more.
Oct 18, 2024, 10:33 AM EST
Amicus Therapeutics FOLD announced that it has signed a licensing agreement with Teva Pharmaceuticals TEVA, which resolves the patent lawsuit filed earlier by FOLD. See more.
Oct 18, 2024, 6:02 AM EST
The United States market has shown robust performance, climbing 1.1% in the last 7 days and rising 36% over the past year, with earnings anticipated to grow by 15% annually. See more.
Oct 17, 2024, 9:40 AM EST
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. See more.
Oct 17, 2024, 9:34 AM EST
Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). See more.